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https://doi.org/10.1016/j.stemcr.2018.06.008SUMMARYOncogenic KRAS mutations in hematopoietic stem cells cause RAS-associated autoimmune lymphoproliferative syndrome-like disease
(RALD). KRAS plays essential roles in stemness maintenance in some types of stem cells. However, its roles in pluripotent stem cells
(PSCs) are poorly understood. Here, we investigated the roles of KRAS on stemness in the context of induced PSCs (iPSCs). We used
KRASmutant (G13C/WT) and wild-type isogenic (WT/WT) iPSCs from the same RALD patients, as well as wild-type (WTed/WT) and het-
erozygous knockout (Ded/WT) iPSCs, both obtained by genome editing from the sameG13C/WTclone. ComparedwithWT iPSCs, G13C/
WT iPSCs displayed enforced retention of self-renewal and suppressed capacity for neuronal differentiation, while Ded/WT iPSCs showed
normalized cellular characteristics similar to those of isogenic WTed/WT cells. The KRAS-ERK pathway, but not the KRAS-PI3K pathway,
was shown to govern these G13C/WT-specific phenotypes, indicating the strong impact of the KRAS-ERK signaling upon self-renewal
and differentiation propensity in human iPSCs.INTRODUCTION
The small GTPase RAS family proteins (KRAS, NRAS, and
HRAS) are controlled through the exchange of the GDP-
bound form for the GTP-bound one, which then allows
RAS to bind various effectors, such as RAF, phosphoinosi-
tide 3-kinase (PI3K), and RALGDS (Castellano and Down-
ward, 2010; D’Adamo et al., 1997; Moodie et al., 1993;
Vivanco and Sawyers, 2002; Vojtek et al., 1993). RAS-asso-
ciated signaling pathways play important roles in multiple
cellular functions, such as cell growth, migration, adhe-
sion, survival, and differentiation. The mutations at hot-
spots (G12, G13, and G61) in the RAS genes cause
accumulation of the GTP-bound form due to defective
intrinsic GTP hydrolysis activity and resistance to
GTPase-activating proteins (Prior et al., 2012). These onco-
genic mutations in the RAS genes are observed in approxi-
mately 30% of all human cancers. KRAS is one of the most
widely known oncogenes and is frequently found to be
mutated in colorectal, pancreatic, and lung cancers (Adjei,
2001).
Oncogenic KRAS has been reported to play a significant
role in stem cell activities in some types of cancers. For
example, it has been shown that oncogenic KRAS in colon380 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018 j ª 2018 The A
This is an open access article under the CC BY-NC-ND license (http://creativcancers enhances the embryonic stem (ES) cell-like pro-
gram during human colon cancer initiation from adenoma
to carcinoma, and activates cancer stem cell (CSC) proper-
ties in APC-mutated cells through the MAPK pathway (Le
Rolle et al., 2016; Moon et al., 2014). In addition, onco-
genic KRAS has been reported to enhance stemness in
CSCs in pancreatic cancers through the PI3K/AKT/
mammalian target of rapamycin pathways (Matsubara
et al., 2013).
The mutations in the RAS pathway are known to be
involved not only in cancers, but also in other disorders
including a series of congenital diseases and an acquired
hemato-immunological disease, namely, RAS-associated
autoimmune lymphoproliferative syndrome (ALPS)-like
disease (RALD). RALD has been reported as a disease
affecting the hemato-immune system, caused by a somatic
KRAS or NRAS mutation in hematopoietic lineage cells.
RALD patients exhibit ALPS- and/or juvenile myelomono-
cytic leukemia-like symptoms, including autoimmune
cytopenia, lymphadenopathy, and hepatosplenomegaly
(Niemela et al., 2011; Shiota et al., 2015; Takagi et al.,
2011). Moreover, a RALD patient exhibiting intestinal
Behcet’s disease-like phenotypes was reported (Moritake
et al., 2016). In RALD, individual patients have clonesuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
withKRAS orNRASmutation andwild-type clones together
in hematopoietic lineage cells in a mosaic state, allowing
the generation of a set of isogenic induced pluripotent
stem cell (iPSC) clones from the same patients. RALD pa-
tient-derived iPSCs therefore represent a unique experi-
mental tool that is useful for studying basic RAS biology,
particularly the roles of KRAS on stemness maintenance
in the context of PSCs.
In the culture of human embryonic stem cells (ESCs) and
iPSCs, basic fibroblast growth factor (bFGF) is essential to
maintain their stemness through activating the MAPK
and PI3K pathways. If human ESCs and iPSCs are cultured
without bFGF, they lose their stemness and start to differ-
entiate (Chen et al., 2011; Ding et al., 2010; Lanner and
Rossant, 2010; Levenstein et al., 2006; Li et al., 2007). These
observations clearly demonstrate the importance of bFGF-
mediated signaling for the maintenance of human iPSCs
and ESCs. However, it remains largely unknown how the
status of effector molecules including KRAS located down-
stream in bFGF signals affects stemnessmaintenance in hu-
man iPSCs.
Here, we investigated the roles of KRAS on stemness
maintenance in the context of human iPSCs by using
isogenic KRAS mutant (G13C/WT) and wild-type (WT/
WT) iPSCs, generated from two RALD patients with the
same somatic KRAS mutation. By genome-editing tech-
niques, we succeeded in generation of ‘‘gene-corrected’’
wild-type iPSCs (WTed/WT) and heterozygous knockout
iPSCs (Ded/WT), both of which could serve as relevant con-
trols for the experiments. Using this series of isogenic
iPSCs, we determined how the status of KRAS could impact
upon stemness maintenance in human iPSCs and differen-
tiation propensity under permissive conditions.RESULTS
Establishment of iPSC Clones from RALD Patients
We generated iPSCs from CD34+ hematopoietic stem/pro-
genitor cells of two RALD patients with the same somatic
G13C heterozygous mutation in the KRAS gene (Tables S1
and S2). We obtained mutant (G13C/WT) and isogenic
wild-type (WT/WT) iPSC clones from each patient as
confirmed by direct sequencing (Figure 1A). The presence
of oncogenic mutations other than KRAS was excluded by
whole exome sequencing (Table S3). Karyotyping showed
that all RALD patient-derived iPSC clones exhibited a
normal 46XY karyotype (Figure 1B). All iPSC clones ex-
pressed the markers, OCT4, NANOG, TRA-1-60, and
SSEA4 (Figure 1C).
To assess how the status of KRAS affects stemness and dif-
ferentiation in these iPSC clones, we investigated changes
in gene expression levels of stemness and lineage markersafter in vitro embryoid body (EB)-mediated differentiation
for 16 days. In the suspension culture to induce differenti-
ation, all iPSC clones formed EBs (Figures 2A and S1A).
However, RNA sequencing (RNA-seq) analysis showed
that there were clear differences in stemness and lineage
marker expression between WT/WT and G13C/WT geno-
types in case no. 2 (Figure 2B). Following 16-day differenti-
ation, mRNA levels of stemness markers decreased over
time in the WT/WT genotype, whereas they seemed to
remain high in the G13C/WT cells, especially R2-1 clone.
In general, mRNA levels of lineage markers were elevated
upon differentiation in both WT/WT and G13C/WT cells.
The expression levels of endodermal and earlymesodermal
markers were higher in the G13C/WTcells than in theWT/
WT counterparts, whereas those of ectodermal markers in
the G13C/WT genotype were lower. The same trend in
expression differences of stemness (POU5F1 and NANOG),
mesodermal (EOMES and T), and ectodermal markers
(PAX6 and ASCL1) was confirmed in qRT-PCR analysis of
case no. 2 (Figure 2C). However, mRNA levels were compa-
rable in two genotypes regarding endodermal markers
(FOXA2 and SOX17) after differentiation. Although PAX6
mRNA levels after differentiation were comparable be-
tween groups, the clear difference in two genotypes was
also observed on POU5F1, NANOG, and ASCL1 in qRT-
PCR analysis of case no. 1 (Figure S1B). Thus, we focused
on the marked differences of stemness and ectodermal
markers in the two genotypes.
Considering that both PAX6 and ASCL1 are transcription
factors essential for neurogenesis (Ali et al., 2014; Castro
and Guillemot, 2011; Osumi et al., 2008), we compared
expression of neuronal markers bIII-Tubulin andMAP2 be-
tweenWT/WTand G13C/WT iPSCs after 16-day differenti-
ation (Figure 2D). In differentiated cells harboring theWT/
WT genotype, many bIII-Tubulin- and MAP2-double-posi-
tive neurons with long extending neurites could be seen.
In contrast, there were fewer bIII-Tubulin- and MAP2-
double-positive neurons differentiated from G13C/WT
iPSCs. There were some neurites positive for bIII-Tubulin
but negative for MAP2 in clone R2-1. In the case of clone
R2-3, neurites of bIII-Tubulin- and MAP2-double-positive
cells were few in number and very short in length. Similar
observations were also made from immunostaining of case
no. 1-derived iPSC line differentiated cells. bIII-Tubulin-
positive neurons were seen in differentiated C1-1 cells,
whereas no positive cells were detected in differentiated
R1-1, R1-2, or R1-3 cells (Figure S1C). These results indicate
that oncogenic KRAS impacts upon self-renewal capacity
and differentiation propensity in human iPSCs.
Rescue of the KRASMutation by Genome Editing
To validate whether the phenotypes described above were
attributable to the specific KRAS genotype, we attemptedStem Cell Reports j Vol. 11 j 380–394 j August 14, 2018 381
Figure 1. Establishment and Characterization of iPSC Clones Generated from Two RALD Patients
(A) KRAS sequences of wild-type (WT/WT) and mutant (G13C/WT) iPSC lines derived from two RALD patients (cases no. 1 and no. 2).
A position of mutation (G to T) is indicated by red letters.
(B) Karyotypes of WT/WT and G13C/WT iPSC lines derived from case no. 2 (RALD patient).
(C) Immunocytochemistry of iPSC markers (OCT4, NANOG, TRA-1-60, and SSEA4) in WT/WT and G13C/WT iPSC clones. Ho, Hoechst 33342.
Scale bar, 100 mm.
See also Tables S1 and S2.
382 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018
Figure 2. Different Differentiation Propensity between WT/WT and G13C/WT iPSCs Generated from Two RALD Patients
(A) Embryoid body formation of WT/WT and G13C/WT iPSC clones from case no. 2. Scale bar, 200 mm.
(B) RNA-seq data showing gene expression levels of stemness and lineage markers from case no. 2 samples before and after 16-day in vitro
differentiation. Undiff. and Diff., undifferentiated iPSCs and differentiated cells, respectively.
(legend continued on next page)
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to generate ‘‘gene-corrected’’ wild-type iPSCs from a G13C/
WT clone. For genome editing, we used the CRISPR/Cas9
system for one G13C/WT iPSC clone from RALD patient
no. 1 (clone R1-2) (Figure S2A). Through homologous
recombination, we were able to obtain genome-edited
wild-type homozygous clones (clone; C8 and H2, WTed/
WT; ‘‘ed’’ meaning genome-edited). In addition, we could
obtain heterozygous knockout clones (Ded/WT) from the
same genome-editing experiment (clone; A1 and D2, Fig-
ure S2B). We checked the top five off-target candidate sites
of the single guide RNA used in this procedure and
observed no off-target cleavage (Figure S2C). Western blot-
ting analysis confirmed that KRAS expression levels were
comparable in WTed/WT and G13C/WT clones (clone; F4
and G4, which are non-edited clones). KRAS expression
was lower in Ded/WT clones compared with the other two
cell types, consistent with the haploinsufficient state
(Figure S2D).
These clones were subjected to 16-day in vitro differenti-
ation and examined for the expression of stemness genes
and three-germ layer markers. In the suspension culture
to induce differentiation, all clones formed EBs (Fig-
ure S3A). Analysis by qRT-PCR showed that expression
levels of POU5F1 and NANOG remained high in G13C/
WTcells (F4 and G4) after 16-day differentiation, although
they decreased in WTed/WT (clone; C8 and H2) and
Ded/WT cells (clone; A1 and D2). Transcription of ASCL1
mRNA in G13C/WT cells was not induced upon differenti-
ation, whereas it showed clear induction in WTed/WT and
Ded/WT cells (Figure S3B). Expression of the neuronal line-
age markers, bIII-Tubulin and MAP2, also became more
intense in WTed/WT clones in comparison with G13C/
WT mutant cells (Figure S3C). These results demonstrated
that gene-correction in the KRAS allele was enough to
normalize the phenotypes inherent to iPSCs carrying the
G13C/WT genotype.
Enforced Retention of Self-Renewal by G13C/WT
iPSCs in the Absence of bFGF
Based on the results of in vitro differentiation assays, we
speculated that there could be different expression patterns
of genes relating to stemness, self-renewal, and pluripo-
tency, between WT/WT and G13C/WT iPSCs. RALD pa-
tient-derived iPSCs were cultured with or without bFGF
for 5 days, after which global gene expression was moni-
tored by microarray. Scatterplots between the two combi-
nations of iPSC lines and culture conditions are depicted(C) qRT-PCR analysis of 16-day in vitro differentiated cells fromWT/WT
experiments; mean ± SEM).
(D) Immnunocytochemistry of bIII-Tubulin and MAP2 in 16-day in vitr
from case no. 2. Scale bar, 50 mm.
See also Figures S1–S3.
384 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018in Figure 3A. In the presence of bFGF, there was a high de-
gree of correlation in gene expression pattern betweenWT/
WT and G13C/WT iPSCs (Figure 3A, upper left). However,
the extent of correlation between WT/WT and G13C/WT
cells decreased when they were cultured without bFGF for
5 days (Figure 3A, upper right). Comparison in gene expres-
sion for WT/WT iPSCs between two conditions, i.e., with
and without bFGF, showed marked changes, characterized
by downregulation of stemness genes (POU5F1 and
NANOG) and upregulation of ectodermal genes (PAX6) in
the absence of bFGF (Figure 3A, lower left). In sharp
contrast, there were no changes in gene expression
observed in G13C/WT cells even when they were cultured
without bFGF (Figure 3A, lower right).
Figure 3B is a heatmap of stemness and linage markers.
Stemness markers, including POU5F1, NANOG, and MYC,
were expressed at a high level in both WT/WT and G13C/
WT iPSC lines cultured in the presence of bFGF (four lanes
in the middle).
When cells were cultured without bFGF, the expression
of these genes diminished in the case of the WT/WT geno-
type (two lanes on left, C2-1 and C2-2; w/o). On the con-
trary, they remain highly expressed, almost unchanged in
the G13C/WT genotype (two lanes on right, R2-1 and
R2-2; w/o). The dendrogram indicated that the expression
pattern was more closely related between G13C/WT sam-
ples cultured with bFGF and those without bFGF than be-
tween G13C/WT iPSCs and WT/WT iPSCs both in culture
with bFGF. This was also reflected in the results of the scat-
terplots in Figure 3A. Among linage markers, ectodermal
marker expression tended to be elevated even after 5-day
culture without bFGF in WT/WT cells (two lanes on left,
C2-1 and C2-2; w/o), but it did not in bFGF-depleted
G13C/WT cells (third and fourth lanes from left, R2-1
and R2-2, w/o). Taken together, these microarray data
demonstrate enforced retention of self-renewal of G13C/
WT iPSCs in the absence of bFGF.
Correlation between KRAS Genotypes and Stemness
Maintenance Potentials Quantified by an Imaging
Approach
To analyze the enforced retention of self-renewal at the
protein level, the expression of stemness markers was
confirmed by immunocytochemistry staining. Upon
bFGF removal, cell morphology changed to a more flat-
tened appearance and the immunocytochemical expres-
sion of stemnessmarkers (OCT4 andNANOG) dramaticallyand G13C/WT iPSC clones derived from case no. 2 (n = 3 independent
o differentiated cells from WT/WT and G13C/WT iPSC clones derived
Figure 3. Microarray Analysis of Isogenic WT/WT and G13C/WT
KRAS Mutant iPSCs from a RALD Patient and Those Cultured
without bFGF for 5 Days
(A) Scatterplots with coefficients of correlation (R) for whole genes
in WT/WT and G13C/WT iPSCs cultured with (w/) or without (w/o)
bFGF for 5 days. Two clones per genotype were used: C2-1 and C2-2
for WT/WT; R2-1 and R2-2 for G13C/WT, derived from case no. 2. In
this analysis, data of the same genotypes were averaged. Positions
of POU5F1 (two probes), NANOG, and PAX6 (two probes) are indi-
cated. The green lines indicate the diagonal and 2-fold changes
between the two samples.
(B) A heatmap with hierarchical clustering for stemness and lineage
marker expression in the same samples as described above.decreased in WT/WT iPSCs (Figure 4A, left panel, C1-1,
C2-1, and C2-2). In contrast, cell morphology and stem-
ness marker expression in G13C/WT iPSCs remained
almost unaffected (R1-2, R2-1, and R2-3). Regarding other
stemness markers, TRA-1-60 also decreased in expression,
whereas SSEA4 did not do so much in WT/WT iPSCs by
the depletion of bFGF for 5 days (Figure 4A, right panel).
Quantitative imaging analysis of bFGF-deprived cells
showed that OCT4+ rates of G13C/WT clones (R1-1, -2,
and -3) remained higher than 75% of vehicle treatment,
whereas those of the WT/WT clone C1-1 reduced to levels
less than 25% (Figure 4B). Similar results were obtained in
iPSC clones derived from case no. 2 (Figure 4C). Combining
the data of the three RALD iPSC clones for each genotype
from case no. 2, we examined the effects of genotype
and bFGF depletion on OCT4 expression by using two-
way ANOVA, and obtained statistically significant results
(Table S4).
We next compared oncogenic KRAS genotype-associated
changes in OCT4+ rates in genome-edited iPSCs after
removal of bFGF. The OCT4+ area of WTed/WT cells was
drastically reduced compared with G13C/WT cells. Inter-
estingly, the OCT4+ area of Ded/WT cells was significantly
reduced comparedwith that ofWTed/WTcells (Figure S3D).
The detailed summary of statistical analysis is shown in
Table S4.
We then investigated if mutant iPSCs retaining stemness
marker expression after bFGF depletion also maintained
pluripotency. To this end, the iPSCs pre-depleted of bFGF
for 5 days were reseeded as single cells and cultured for
another 7 days back in bFGF-replete culture. As shown in
Figure 4D, G13C/WT cells formed many iPSC colonies
which were alkaline phosphatase (ALP)-positive, whereas
only a few colonies appeared in WT/WT cells (Figure 4D).
ALP+ colony numbers in G13C/WT genotype were signifi-
cantly higher than those in WT/WT genotype (Figure 4E).
These results confirmed oncogenic KRAS genotype-associ-
ated enhancement in retention of self-renewal capacity in
iPSCs.
Biochemical Analysis on KRAS Activity and
Downstream ERK and AKT Pathways
To determine the mechanisms underlying the KRAS
mutant-specific phenotypes as described above, we first
examined the existing amount of KRAS-GTP by GST-
RAF1 pull-down assays. We observed significantly larger
amounts of KRAS-GTP in G13C/WT iPSCs compared with
WT/WT iPSCs under both conditions with and without
bFGF (Figures 5A and 5B). Importantly, KRAS-GTP levels
still remained high in G13C/WT iPSCs, but not in
WT/WT iPSCs, even in the absence of bFGF, indicating
constitutive activation of KRAS in G13C/WT iPSCs
(Figures 5A and 5B). Consistent with these results, theStem Cell Reports j Vol. 11 j 380–394 j August 14, 2018 385
Figure 4. Enforced Retention of Self-Renewal of KRAS G13C/WT Mutant iPSCs in the Absence of bFGF, Revealed by Immunocy-
tochemical Reactivity for Stemness Markers, Colony Formation, and Alkaline Phosphatase Staining
(A) Immunocytochemistry of stemness markers (OCT4, NANOG, TRA-1-60, and SSEA-4) in WT/WT and G13C/WT iPSC clones from RALD
patients cultured without bFGF for 5 days. Scale bar, 100 mm.
(B and C) Quantitative imaging analysis for OCT4 in iPSC clones from RALD patients, cases no. 1 (B) and no. 2 (C), respectively (n = 8
independent experiments; mean ± SEM; ***p < 0.001; two-way ANOVA followed by Bonferroni’s multiple comparison test).
(legend continued on next page)
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Figure 5. Biochemical Analysis on the
ERK and AKT Pathways Activity in En-
forced Retention of Self-Renewal of
KRAS G13C/WT iPSCs
(A) GST-RAF1 pull-down assays of RALD
patient-derived iPSC (WT/WT and G13C/WT)
clones from case no. 1 and no. 2 cultured
with (w/) or without (w/o) bFGF for 3 days.
(B) Densitometric analysis of western blot-
ting results shown in (A). Each point in-
dicates an individual clone’s value (n = 4–6
independent clones; mean ± SEM; ***p <
0.001; Student’s t test or Mann-Whitney
test).
(C) Western blot analysis of WT/WT and
G13C/WT iPSC clones stimulated for the
indicated time course after the removal of
bFGF for 3 days. ERK and AKT were analyzed
for their phosphorylation. b-Tubulin was
used as an internal control.
(D) Western blot analysis of WT/WT and
G13C/WT clones cultured w/ or w/o bFGF for
2 days. Phosphorylation of ERK and AKT was
analyzed as in (C).
(E and F) Densitometric analysis of ERK (E)
and AKT (F), respectively, in (D). Each
point indicates an individual clone’s value
(n = 4–6 independent clones; mean ± SEM;
***p < 0.001; Student’s t test or Mann-
Whitney test). GST, glutathione S-trans-
ferase; RBD, Ras-binding domain.
See also Figure S4.same pattern was observed when genome-edited WTed/
WT clones were compared with G13C/WT clones (Figures
S4A and S4B). Furthermore, KRAS-GTP levels in Ded/WT
clones were significantly reduced compared with those(D) Whole six-well (left) and magnified images (right) of alkaline ph
Scale bar, 100 mm.
(E) Quantification of ALP-positive (ALP+) colony number in (D) (n = 3
two-way ANOVA followed by Bonferroni’s multiple comparison test).
See also Figure S3; Table S4.in WTed/WT clones in the absence of bFGF (Figures S4A
and S4B).
Next, we analyzed the phosphorylation levels of ERK
and AKT in G13C/WT and WT/WT iPSCs to determineosphatase (ALP)-stained WT/WT (C2-1) and G13C/WT (R2-1) cells.
independent experiments; mean ± SEM; **p < 0.01; ***p < 0.001;
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Figure 6. Pharmacological Analysis on the
Involvement of the RAF-MEK-ERK and
PI3K-AKT Pathways in Enforced Retention
of Self-Renewal of KRAS G13C/WT iPSCs
(A and B) Effects of MEK inhibitors
(PD184352 and U0126) on OCT4+ area (A)
(n = 3 independent experiments; mean ±
SEM) and phosphorylation of ERK and AKT
(B), respectively, in G13C/WT iPSCs (clone
R1-2).
(C and D) Effects of RAF inhibitors
(ZM336372 and AZ628) on OCT4+ area (C)
(n = 3 independent experiments; mean ±
SEM) and phosphorylation of ERK and AKT
(D), respectively, in G13C/WT iPSCs (clone
R1-2).
(E) Representative fluorescent images of
G13C/WT iPSCs (clone R1-2) treated with the
compounds at indicated concentrations.
Vehicle, 0.1% DMSO. Scale bar, 100 mm.
See also Figure S5; Table S5.downstream signaling activity in KRAS-signaling path-
ways. Upon bFGF stimulation for the indicated times
after its removal, the ERK pathway was prominently
upregulated in both cell types, whereas it showed only
slight upregulation of pAKT (Figure 5C). To see if
sustained activation of the downstream pathways from
KRAS occurred in G13C/WT iPSCs even after bFGF
deprivation, we compared phosphorylation levels of
ERK and AKT after culturing cells with or without
bFGF. Although there was only a marginal increase
in pERK in G13C/WT iPSCs compared with WT/WT
counterparts in the presence of bFGF (p = 0.0936), sig-
nificantly higher pERK levels were maintained in
the mutant clones than the control in the absence
of bFGF (p < 0.001) (Figures 5D and 5E). On the
other hand, there was no significant difference in pAKT388 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018levels between WT/WT and G13C/WT iPSCs in either
case with or without bFGF (Figures 5D and 5F). Using
genome-edited iPSC clones, retention of pERK expres-
sion in the absence of bFGF was also confirmed
for G13C/WT clones when compared with WTed/WT
clones. Notably, Ded/WT clones showed pERK levels
that were significantly lower than those in WTed/
WT clones in the absence of bFGF (p < 0.05), which is
similar to aforementioned results and consistent with
the idea that these artificial control clones exhibit hap-
loinsufficiency and thus ‘‘loss-of-function’’ phenotypes
(Figures S4C and S4D). These results indicate that
bFGF stimulation appears to act through the ERK
signaling pathway and that there is sustained activity
of KRAS-ERK signaling in G13C/WT iPSCs despite bFGF
withdrawal.
Figure 7. Effects of a MEK Inhibitor on
Suppressed Neuronal Differentiation in
G13C/WT iPSCs
(A) qRT-PCR analysis of a neuronal lineage
marker (ASCL1) in 16-day differentiated
cells from WT/WT (clones C1-1 and C2-1)
and G13C/WT iPSCs (clones R1-2 and R2-1)
treated with a MEK inhibitor (PD184352) at
the concentrations of IC20, IC50, and IC80
values as described in Table S5, or 0.1%
DMSO (vehicle) (n = 3 independent experi-
ments; mean ± SEM; *p < 0.05; **p < 0.01,
***p < 0.001; one-way ANOVA followed by
Dunnett’s test).
(B) Immnunocytochemistry of bIII-Tubulin
in 16-day differentiated cells from WT/WT
and G13C/WT iPSCs treated with PD184352
as described above. Scale bar, 100 mm. PD,
PD184352.Pharmacological Analysis on the Involvement of the
MEK-ERK and PI3K Pathways in the Enforced
Retention of Self-Renewal and Suppressed Neuronal
Differentiation Propensity of G13C/WT iPSCs
Finally, to investigate which downstream pathway from
KRAS was responsible for the retained OCT4 expression
in themutant clones, we performed pharmacological inter-
vention using kinase-specific inhibitors targeting the RAF-
MEK and PI3K pathways (Favata et al., 1998; Hall-Jackson
et al., 1999; Montagut et al., 2008; Powis et al., 1994; Se-
bolt-Leopold et al., 1999; Vlahos et al., 1994) (Figure S5A).
As expected, the retention of OCT4 expression after bFGF
removal in G13C/WT iPSCs was reversed by treatment
with MEK inhibitors (PD184352 and U0126) (Figures 6A
and S5B). Western blot analysis showed that pERK levels
were diminished byMEK inhibitors at the same concentra-
tions that induced the inhibition of OCT4 expression,
while pAKT levels were not affected (Figure 6B). As for
RAF inhibitors, AZD628 decreased the OCT4+ rate, whereas
ZM336372 led to an increased OCT4+ rate (Figures 6C and
S5C). Consistent with these results, AZ628 decreased pERK
levels, but ZM336372 treatment led to an increase in pERK(Figure 6D). Clone R2-1 also displayed the same results as
clone R1-2 (Figures S5E and S5F).
When these compounds diminished OCT4+ areas, a part
of OCT4– cells exhibited flattened morphology especially
in the treatment of MEK inhibitors, which resembled that
of WT/WT iPSCs cultured without bFGF (Figure 6E).
Regarding PD184352, the concentrations that induced
20%, 50%, and 80% (IC20, IC50, and IC80) inhibition rela-
tive to vehicle were determined for all clones (Figure S5G;
Table S5). Among PI3K inhibitors, LY294002 showed a par-
tial decrease in the OCT4+ rate, whereas wortmannin did
not affect that, although it prominently decreased pAKT
levels (Figures S5D, S5H, and S5I).
To ask whether the MEK-ERK pathway was also respon-
sible for the suppressed neuronal differentiation observed
in G13C/WT iPSCs, mutant iPSCs (clones R1-2 and R2-1)
were treatedwith PD184352 during 16-day in vitro differen-
tiation. qRT-PCR analysis showed thatmRNA expression of
ASCL1 increased following treatment with PD184352 in a
concentration-dependent manner (Figure 7A). Immunore-
active bIII-Tubulin appeared in greater density in differen-
tiated cells from G13C/WT iPSCs following treatmentStem Cell Reports j Vol. 11 j 380–394 j August 14, 2018 389
with PD184352 in a concentration-dependent manner
(Figure 7B). These data support the notion that KRAS
mutant-specific phenotypes depend mostly on the RAF-
MEK-ERK pathway, but not the PI3K-AKT pathway.DISCUSSION
In the present study, we established KRAS mutant and
isogenic wild-type iPSC clones from two RALD patients
sharing the same somatic heterozygous KRAS G13C muta-
tion. In comparison with the isogenic iPSC clones, we
showed that activated KRAS with the G13C mutation
conferred retained self-renewal of undifferentiated cells
and difficulty in differentiation into neurons under permis-
sive conditions. In addition, we generated genome-edited
wild-type (WTed/WT) and heterozygous knockout (Ded/
WT) iPSCs from a G13C/WT clone. The phenotypes of
parental G13C/WT iPSCs were rescued in WTed/WT iPSCs,
and lower self-renewal and higher neuronal differentiation
potentials compared with WTed/WT iPSCs was observed in
Ded/WT iPSCs. Accordingly, we concluded that the pheno-
types are KRAS G13C mutation specific.
First, we found retained high expression of stemness
markers in G13C/WT iPSCs, which was observed not
only when cells were cultured without bFGF for 5 days,
but also in 16-day in vitro differentiation. Global gene
expression analysis identified differential expression pro-
files between G13C/WT and WT/WT iPSCs in genes
relating to self-renewal of undifferentiated cells, including
POU5F1 and NANOG. Their expression was retained at a
high level despite the removal of bFGF, suggesting enforced
retention of self-renewal of G13C/WT iPSCs. Furthermore,
clear differences in the size of OCT4+ cell populations be-
tween WT/WT and G13C/WT iPSCs could be detected in
the 5-day bFGF-depletion assays. The capacity for retaining
OCT4 expression was removed by rescuing the G13C allele
(WTed/WT), and lowered with the G13C-specific knockout
(Ded/WT). Thus, we concluded that the enforced retention
of self-renewal was aKRASmutation-specific phenotype. In
general, bFGF is an essential factor for maintaining human
ESC and iPSC pluripotency through downstreamMEK-ERK
and PI3K-AKT pathways (Ding et al., 2010; Lanner and Ros-
sant, 2010; Li et al., 2007). We postulated that the retained
self-renewal of undifferentiated cells observed in G13C/
WT iPSCs was caused by the constitutive activation of
KRAS and its downstream signals even though iPSCs were
cultured without bFGF.We attempted to detect KRASmuta-
tion-specific hyper-activation of the KRAS pathways. As ex-
pected, RAF1 pull-down assays showed hyper-activated
KRAS in G13C/WT iPSCs in the absence of bFGF. Western
blot analysis showed that the ERK pathway was largely up-
regulated, but only slight upregulation was observed in the390 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018AKT pathway upon temporal stimulation with bFGF.More-
over, pERK was more upregulated in G13C/WT iPSCs
compared with WT/WT iPSCs, but such a trend was not
observed in the case of pAKT when cultured without
bFGF for a few days. Taken together, the MEK-ERK
pathway, but not the PI3K pathway, was considered to be
the main pathway involved in the bFGF signal resulting
in KRASmutant-specific phenotypes.
To further investigate whether the ERK pathway was
responsible for the enforced retention of self-renewal, we
performed pharmacological analysis using specific kinase
inhibitors. MEK inhibitors (PD184352 and U0126)
decreased OCT4+ area rates of G13C/WT iPSCs cultured
in the absence of bFGF in a concentration-dependent
manner. In terms of RAF inhibitors, paradoxical results
were obtained between AZ628 and ZM336372; AZ628 low-
ered OCT4+ area rates, whereas ZM336372 elevated them.
It has been reported that some RAF inhibitors block MEK-
ERK signaling in cells with mutant BRAF, but enhance
signaling in cells withwild-type BRAF. These RAF inhibitors
include PLX4720 (vemurafenib), GDC-0879 (BRAF inhibi-
tors), and ZM336372 (a CRAF inhibitor) (Hall-Jackson
et al., 1999; Hatzivassiliou et al., 2010; Poulikakos et al.,
2010). Interestingly, among the RAF inhibitor examined,
AZ628, a pan-RAF inhibitor, does not induce phosphoryla-
tion ofMEK or hyper-proliferation of KRASWT/BRAFWTcells
(Hatzivassiliou et al., 2010). Our data fromG13C/WT iPSCs
were in agreement with these previous reports. The PI3K-
AKT pathway is also known to be important inmaintaining
stemness of human ESCs (Ding et al., 2010; Li et al., 2007).
The addition of LY294002 in particular led to a decrease in
OCT4+ area rates, while wortmannin did not affect them,
although pAKT was effectively lowered by wortmannin
treatment. Recently, LY294002 has been reported to act
as not only a PI3K inhibitor, but also as a bromodomain
and extraterminal domain (BET) inhibitor (Dittmann
et al., 2014). BRD4, amember of the BET family of proteins,
is required for maintenance in human ESCs through the
regulation of pluripotency genes, including POU5F1 and
NANOG (Di Micco et al., 2014). Assuming that the effects
of LY294002 on OCT4+ area rates were caused by BET inhi-
bition, the involvement of PI3K in the retained self-
renewal of undifferentiated cells would be moderate under
our assay conditions. This is because wortmannin, another
chemotype PI3K inhibitor, did not decrease OCT4+ area
rates at all. Therefore, it could be demonstrated that the en-
forced retention of self-renewal in G13C/WT iPSCs derived
from RALD patients was caused mainly by retained KRAS
activation and subsequent prolonged hyper-activation of
the RAF-MEK-ERK signals.
In this study, we found suppression of neuronal differen-
tiation from G13C/WT iPSCs as shown in 16-day in vitro
differentiation experiments. So far, mutations in the RAS
pathway have been reported to be implicated in neural dis-
eases. The RASopathies, such as Noonan syndrome, Cost-
ello syndrome (CS), cardio-facio-cutaneous syndrome,
and neurofibromatosis type 1 (NF-1), are developmental
syndromes caused by germline mutations in genes
involved in the RAS-MEK pathways. These disorders are
all characterized by neurological symptoms, such asmental
retardation, cognitive impairment, and increased anxiety.
These abnormalities are thought to originate from dysregu-
lated differentiation of neuronal progenitor cells, based on
structural CNS characteristic to the RASopathy patients,
and the results obtained from animal model studies (Axel-
rad et al., 2011; Costa et al., 2002). In neural differentiation,
bFGF-ERK signaling is known to inhibit PAX6 induction
and act as an inhibitory signal to neural induction in hu-
man ESCs (Greber et al., 2010). Moreover, activated RAS
signaling caused bymutations of KRAS orNF-1 has been re-
ported to lead to enhanced proliferation of neuronal pro-
genitor cells and aberrant differentiation into neurons in
mouse models (e.g., shorter neurites) (Bender et al., 2015;
Brown et al., 2012; Rooney et al., 2016). Recently, Rooney
et al. reported the generation of CS patient-derived iPSCs
harboring a heterozygous constitutively active G12S muta-
tion inHRAS. By demonstrating an increased population of
PAX6+/MAP2 cells and shorter neurite length in neurons
differentiated from HRAS-mutated iPSCs, they suggested
that activated HRAS led to an extended neuronal progeni-
tor phase and difficulty in maturation of neurons (Rooney
et al., 2016). In this study, we manifested the decreased
expression of the neuronal markers, particularly ASCL1,
and reduced bIII-Tubulin+/MAP2+ cells in G13C/WT iPSC
lines cultured for 16 days in a differentiation-permissive
condition. Despite taking into consideration the differ-
ences in experimental settings between studies, our results
would further strengthen the idea that constitutive RAS
activation in general likely has the potential to affect fates
of stem cells under differentiation-permissive conditions.
We speculated that the perturbation of neuronal differenti-
ation in G13C/WT iPSCs occurred mainly due to sustained
KRAS activity despite withdrawing bFGF. The inhibited
neuronal differentiation was restored completely by
the rescue of the G13C allele using genome-editing tech-
nology or partially by the treatment of an MEK inhibitor,
PD184352. Our findings are in agreement with the previ-
ous paper reporting that FGF signaling inhibits neural
induction, and inhibition of FGF/ERK upregulates a neuro-
ectodermal fate determinant in human ESCs (Greber et al.,
2011).
Overall, our data indicated the significance of KRAS sta-
tus for the maintenance of iPSC stemness, which would
eventually affect aspects such as self-renewal and differen-
tiation propensity. The roles of oncogenic KRAS in stem-
ness maintenance have been implicated in some types ofstem cells. Oncogenic KRAS plays important roles in the
imposition of ESC-like transcriptional profiles and upregu-
lation of CSC markers, leading to the tumor initiation and
development shown in colorectal and pancreatic cancers
(Le Rolle et al., 2016; Matsubara et al., 2013; Moon et al.,
2014). In a model of retinoic acid (RA)-induced stem cell
differentiation to endoderm, oncogenic KRAS confers on
cells resistance to differentiation associated with the main-
tenance of stem cell characteristics despite RA treatment
(Quinlan et al., 2008). In addition, oncogenic KRAS pro-
motes self-renewal properties and tumor initiation by sup-
pressing non-canonical WNTsignaling (Wang et al., 2015).
These studies suggest that the involvement of oncogenic
KRAS in stemness maintenance might be a common
feature among various types of stem cells, especially in
CSCs. Taken together, the RALD patient-derived isogenic
iPSCs would be applicable to research not only on pathol-
ogy of RALD but also certain aspects of CSCs as a general
tool for studying oncogenicKRAS-driven stem cell dysfunc-
tions. Using this unique and invaluable tool, the develop-
ment of pharmacological treatment will likely be achieved
for RALD, CSCs, and other oncogenicKRAS-related diseases
in the future.EXPERIMENTAL PROCEDURES
Ethics
Bone marrow cell samples from patients were used in accordance
with the Declaration of Helsinki. Written informed consent for
samples to be used for research purposes was obtained from the pa-
tient or patient’s parents. The study was approved by the Ethics
Committee of The Institute of Medical Science, The University of
Tokyo (protocol number, 25-3-0701), the Ethics Committee of
Tokyo Medical and Dental University (approval numbers, 676),
and the Eisai Research Ethics Committee (approval numbers,
2014-0238, 2014-0259, 2015-0238, 2015-0259, 2016-0238, and
2016-0259). The use of viral vectors was approved by the ethics
committees of The Institute of Medical Science, The University
of Tokyo.
Establishment of iPSCs from RALD Patients
Establishment of iPSCs from CD34+ hematopoietic stem/progeni-
tor cells was performed as described previously (Lin et al., 2015;
Takayama et al., 2010) at The Institute of Medical Science, The
University of Tokyo. Mononuclear cells were extracted by Ficoll
density gradient separation from whole bone marrow aspirate ob-
tained from the two individual RALD patients. CD34+ cells were
isolated from this mononuclear fraction by immunomagnetic sep-
aration using a CD34MicroBead Kit (Miltenyi Biotec) according to
the manufacturer’s protocol. Non-integrating Sendai virus (SeV)
vectors harboring human POU5F1, SOX2, KLF4, and c-MYC (Nish-
imura et al., 2011) were used to transduce isolated CD34+ cells for
reprogramming into RALD patient-derived iPSCs. Lipofectamine
RNAi Max (Thermo Fisher Scientific) was used to transfect estab-
lished RALD patient-derived iPSCs with small interfering RNAStem Cell Reports j Vol. 11 j 380–394 j August 14, 2018 391
L527 for the removal of SeV vectors. Established clones were
screened for mutations in the KRAS gene by sequencing genomic
DNA. A proportion of CD34+ cells obtained from both patients
did not carry any KRAS mutation. The resulting iPSC clones free
of themutationwere retained andused as isogenic controls. Karyo-
typing was performed at Nihon Gene Research Laboratories
(Sendai, Japan).
iPSC Maintenance
RALD patient-derived iPSC clones were introduced into Eisai Tsu-
kuba Laboratories from The Institute of Medical Science. Detailed
information of the clones is given in Table S2. In the Eisai Tsukuba
Laboratories, iPSCs were maintained on vitronectin (Thermo
Fisher Scientific)-coated plates in a culture medium for iPSCs,
StemFit (Ajinomoto) added with StemFit’s supplement package
including bFGF and 13 penicillin-streptomycin (P/S; Wako). At
passage, iPSCs were dissociated with TrypLE Select (Thermo Fisher
Scientific) and cultured with 10 mM Y-27632 (Wako), and the me-
dium was changed to Y-27632-free StemFit the next day. The me-
dium was replaced every 2 days, and iPSCs were passaged every 3
or 4 days. Cell culturewas carried out at 37C in a humidified atmo-
sphere of 20% O2. In this study, we used iPSCs at the passage
numbers less than 30 after the introduction into Eisai.
In Vitro EB-Mediated Differentiation
In vitro differentiation was performed basically according to pro-
cedures as described previously (Takahashi et al., 2007). iPSCs
were harvested after cell dissociation with TrypLE Select, and
seeded to six-well ultra-low attachment plates (Corning) in bFGF-
free StemFit containing 10 mM Y-27632 (Wako) to produce EBs.
On the following day, the medium was changed to a fresh one
without Y-27632. After the 8-day suspension culture, EBs were
collected and transferred to 0.1% gelatin (Sigma)-coated plates to
initiate adherent culture. Cells were allowed to differentiate in
bFGF-free StemFit containing 10% fetal bovine serum (Thermo
Fisher Scientific) for additional 8 days. The media were exchanged
basically every 2 days.
Immunocytochemistry
Cells were fixed by 4% paraformaldehyde (Wako) for 30 min at
room temperature. They were blocked and permeabilized in
4% (w/v) Block Ace (AbD Serotec)/cell staining buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, and 0.2% Triton X-100) for
30 min at room temperature. Then, cells were incubated with
primary antibodies in 0.4% (w/v) Block Ace/cell staining buffer
overnight at 4C, and subsequently incubated with appropriate
secondary antibodies with Hoechst 33342 (10 mg/mL; Sigma-
Aldrich) in 0.4% (w/v) Block Ace/cell staining buffer for 1.5 hr at
room temperature. Detailed conditions of antibodies are given in
Table S6. Fluorescence imageswere acquired on an IX73 (Olympus)
or IN-Cell Analyzer (GE Healthcare).
bFGF-Depletion Assays
Cells were dissociated by TrypLE Select, and 2 3 103 cells were
seeded on vitronectin-coated 96-well plates in StemFit containing
Y-27632 (10 mM)with or without bFGF and cultured for 5 days.Me-
dium was changed on day 1, to remove Y-27632, and on day 3.392 Stem Cell Reports j Vol. 11 j 380–394 j August 14, 2018Immunocytochemistry of stemness markers was performed as
described above. In quantitation, OCT4+ and nucleus (Hoechst
33342-stained) areas were measured by an IN-Cell Developer (GE
Healthcare). OCT4+ rates and expected total cell numbers were
calculated as follows:
- OCT4+ rate (%) = total OCT4+ area/Hoechst-positive area 3
100
- Expected total cell numbers = total Hoechst-positive area/me-
dian of individual Hoechst-positive areaColony-Formation Assays and ALP Staining of
Reseeded iPSCs that Had Been Cultured without bFGF
RALD iPSCs (C2-1 and C2-2 of WT/WT clones; R2-1 and R2-2 of
G13C/WT clones) were plated and cultured in StemFit without
bFGF for 5 days. After harvesting cells, they were reseeded into
six-well plates at 1.0 3 104 cells/well (n = 3), and cultured in
StemFit with bFGF.When colonieswere formed 7 days after reseed-
ing, cells were stained for ALP using nitrotetrazolium blue chloride
(400 mM; Sigma-Aldrich) and 5-bromo-4-chloro-3-indolyl phos-
phate p-toluidine salt (400 mM; Sigma-Aldrich) in ALP buffer
(100 mM NaCl, 100 mM Tris-HCl, and 50 mM MgCl2 [pH 9.5]).
ALP+ colony number was measured using BZ-X710 (Keyence).
Pharmacological Examinations
We examined effects of specific inhibitors related to RAS pathways
(Favata et al., 1998; Hall-Jackson et al., 1999;Montagut et al., 2008;
Powis et al., 1994; Sebolt-Leopold et al., 1999; Vlahos et al., 1994)
on bFGF-depletion assays and in vitro differentiation. PD184532
andwortmanninwere purchased from Sigma. U0126was obtained
from Wako. ZM336372, AZ628, and LY294002 were purchased
from Selleck. To exclude the effect of cell toxicity, the concentra-
tions of each compound were selected at the range of lower than
80% cell growth inhibition judged by the percentage of nucleus
number relative to the vehicle treatment in bFGF-depletion assays
(Figures S5B–S5D).
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